MX2016000293A - Biomarcadores del trastrono del espectro autista. - Google Patents

Biomarcadores del trastrono del espectro autista.

Info

Publication number
MX2016000293A
MX2016000293A MX2016000293A MX2016000293A MX2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A
Authority
MX
Mexico
Prior art keywords
autism
metabolites
spectrum disorder
metabolic signatures
autism spectrum
Prior art date
Application number
MX2016000293A
Other languages
English (en)
Spanish (es)
Inventor
Alan Smith
Paul West
Robert E Burrier
Laura Egnash
Preeti Bais
Original Assignee
Stemina Biomarker Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemina Biomarker Discovery Inc filed Critical Stemina Biomarker Discovery Inc
Publication of MX2016000293A publication Critical patent/MX2016000293A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70Machine learning, data mining or chemometrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2016000293A 2013-07-09 2014-07-03 Biomarcadores del trastrono del espectro autista. MX2016000293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844128P 2013-07-09 2013-07-09
US201461996835P 2014-05-14 2014-05-14
PCT/US2014/045397 WO2015006160A2 (en) 2013-07-09 2014-07-03 Biomarkers of autism spectrum disorder

Publications (1)

Publication Number Publication Date
MX2016000293A true MX2016000293A (es) 2016-06-21

Family

ID=52280698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000293A MX2016000293A (es) 2013-07-09 2014-07-03 Biomarcadores del trastrono del espectro autista.

Country Status (6)

Country Link
US (2) US10060932B2 (cg-RX-API-DMAC7.html)
EP (1) EP3019624B1 (cg-RX-API-DMAC7.html)
JP (1) JP6763770B2 (cg-RX-API-DMAC7.html)
CA (1) CA2917483A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016000293A (cg-RX-API-DMAC7.html)
WO (1) WO2015006160A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20190178900A1 (en) * 2016-05-13 2019-06-13 Stemina Biomarker Discovery, Inc. Autism subsets
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
US12080432B1 (en) 2017-06-01 2024-09-03 The Regents Of The University Of Colorado Plasma metabolome as a predictor of biological aging
EP3746796A4 (en) * 2018-01-29 2021-12-22 Stemina Biomarker Discovery, Inc. DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISORDERS BASED ON METABOTYPES CONTAINING AN AMINE
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
CA3136303A1 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for childhood risk of autism spectrum disorder
CN113906296B (zh) * 2019-04-23 2024-11-15 中国医学科学院北京协和医院 基于机器学习的使用代谢物作为标记物的孤独症谱系障碍诊断方法和装置
EP3963323A4 (en) * 2019-05-02 2023-05-31 Stemina Biomarker Discovery, Inc. DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISEASES RELATED TO ALTERED METABOLIC PATHWAYS
US20220146527A1 (en) * 2019-09-17 2022-05-12 Chang Gung University Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms
CA3157694A1 (en) * 2019-10-11 2021-04-15 Stemina Biomarker Discovery, Inc. Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolite concentrations
WO2021076960A1 (en) * 2019-10-16 2021-04-22 Anand Rene Live virus vaccine injury risk
WO2022056646A1 (en) * 2020-09-21 2022-03-24 Molecular You Corporation Method of diagnosis and treatment of autism spectrum disorder
CN116547520A (zh) * 2020-09-21 2023-08-04 分子优公司 孤独症谱系障碍的诊断与治疗方法
JP7753359B2 (ja) * 2020-10-24 2025-10-14 ユニヴェルシテートスピタル バーゼル ヒト血漿中のリゼルギン酸ジエチルアミド(lsd)及び2,3-ジヒドロ-3-ヒドロキシ-2-オキソリセルギド(o-h-lsd)を定量化するための方法
CN113125588B (zh) * 2021-03-17 2022-01-14 广东省农业科学院农业质量标准与监测技术研究所 一种代谢组学分析技术判别鸭屎香单丛茶时空分类的应用
KR102530345B1 (ko) * 2021-08-04 2023-05-10 단국대학교 천안캠퍼스 산학협력단 대사체 프로파일링을 이용한 자폐 스펙트럼 장애의 진단용 조성물 및 이를 포함하는 진단키트
JP2024134052A (ja) * 2023-03-20 2024-10-03 株式会社島津製作所 データ処理方法、データ処理装置およびプログラム

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6708064B2 (en) * 2000-02-24 2004-03-16 Ali R. Rezai Modulation of the brain to affect psychiatric disorders
WO2001079837A1 (en) 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS
US20080154332A1 (en) * 2001-12-24 2008-06-26 The Cleveland Clinic Foundation Modulation of the Brain to Affect Psychiatric Disorders and Functions
US8131473B1 (en) 2004-05-20 2012-03-06 Metabolon, Inc. Data analysis methods for locating entities of interest within large, multivariable datasets
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) * 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20070023677A1 (en) * 2005-06-29 2007-02-01 Perkins Patrick D Multimode ionization source and method for screening molecules
US7949475B2 (en) 2005-08-08 2011-05-24 Metabolon Inc. System and method for analyzing metabolomic data
US7433787B2 (en) 2005-08-08 2008-10-07 Metabolon, Inc. System, method, and computer program product using a database in a computing system to compile and compare metabolomic data obtained from a plurality of samples
CA2646890C (en) 2006-03-21 2012-07-31 Metabolon, Inc. A system, method, and computer program product for analyzing spectrometry data to indentify and quantify individual components in a sample
WO2008124187A1 (en) 2007-04-10 2008-10-16 University Of Medicine And Dentistry Of Nj Biochemical markers for disease states and genes for identification of biochemical defects
CA2693177A1 (en) 2007-07-26 2009-01-29 Phenomenome Discoveries Inc. Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
WO2009032722A1 (en) * 2007-08-29 2009-03-12 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US7884318B2 (en) 2008-01-16 2011-02-08 Metabolon, Inc. Systems, methods, and computer-readable medium for determining composition of chemical constituents in a complex mixture
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
DK200970026A (en) 2009-06-12 2010-12-13 Alfa Laval Corp Ab A centrifugal separator
EP2309276A1 (en) * 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
AU2011232577C1 (en) * 2010-03-22 2016-07-14 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
US9547013B2 (en) 2010-04-29 2017-01-17 Wisconsin Alumni Research Foundation Molecule biomarkers of autism
US8980548B2 (en) * 2010-05-19 2015-03-17 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
EP2598873A4 (en) * 2010-07-28 2013-11-20 Metabolon Inc BIOMARKERS OF PROSTATE CANCER AND METHODS USING THEM
US20140156573A1 (en) * 2011-07-27 2014-06-05 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc
US20140303228A1 (en) * 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
WO2013086365A2 (en) * 2011-12-09 2013-06-13 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same
US10220089B2 (en) * 2012-08-29 2019-03-05 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
BR112015006284A2 (pt) 2012-09-21 2017-07-04 Governing Council Univ Toronto cpmf como um biomarcador para diabetes e métodos associados
JP6339581B2 (ja) * 2012-11-02 2018-06-06 ステミナ バイオマーカー ディスカバリー, インコーポレイテッド ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測
US9910047B2 (en) * 2013-01-31 2018-03-06 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) * 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk

Also Published As

Publication number Publication date
EP3019624A2 (en) 2016-05-18
US11268966B2 (en) 2022-03-08
CA2917483A1 (en) 2015-01-15
EP3019624B1 (en) 2020-09-16
WO2015006160A2 (en) 2015-01-15
JP6763770B2 (ja) 2020-09-30
EP3019624A4 (en) 2017-01-11
US20160169915A1 (en) 2016-06-16
JP2016530504A (ja) 2016-09-29
WO2015006160A3 (en) 2015-11-26
US10060932B2 (en) 2018-08-28
US20190072569A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
MX2016000293A (es) Biomarcadores del trastrono del espectro autista.
BR112017018821A2 (pt) métodos para quantificação de níveis de insulina através de espectrometria de massa
CA2878044C (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
EA201590027A1 (ru) Способы детекции заболеваний или состояний
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
GB2519906A (en) Methods and systems for detecting biological components
BR112017025097A2 (pt) método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem
MX373957B (es) Un método in vitro para detectar un biomarcador de cáncer en un sujeto.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
BR112015019326A2 (pt) dispositivo de registro de amostragem e armazenamento para análise de gás respiratório
NZ618062A (en) Hsp90 combination therapy
EP4220170A3 (en) Method for detecting a solid tumor cancer
GB201305223D0 (en) Reflection detection type measurement apparatus for skin autofluorescence
IN2014MN02101A (cg-RX-API-DMAC7.html)
BR112016010510A2 (pt) método, arranjo e uso do mesmo
IN2014DE01077A (cg-RX-API-DMAC7.html)
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
EP4290231A3 (en) Method for assessing performance of an instrument with liquid chromatography and mass spectrometry functionalities
HK1204061A1 (en) Methods and kits for detecting and diagnosing neurotrauma
EA201300600A1 (ru) Способ диагностики соединительной ткани и его применение
GB201102693D0 (en) Method for identifying neonates at risk for necrotizing enterocolitis
EA201691168A1 (ru) Способы исследования бета-глюкана